2-Cyano-3-hydroxy-4-methyl-2-pentennitril | 40798-08-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Cyano-3-hydroxy-4-methyl-2-pentennitril
• 英文别名: (1-hydroxy-2-methylpropylidene)methane-1,1-dicarbonitrile；2-(1-hydroxy-2-methylpropylidene)propanedinitrile
• CAS: 40798-08-1
• 化学式: C₇H₈N₂O
• 分子量: 136.153
• InChiKey: MDWVQNYUHSGOHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Cyano-3-hydroxy-4-methyl-2-pentennitril 在 一水合肼 作用下， 以 甲醇 、 乙醚 、 乙醇 为溶剂， 反应 10.0h， 生成 3-Propan-2-yl-2,5-dihydropyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors

  摘要：

  The 70-kDa ribosomal protein S6 kinase (p70S6K) is part of the PI3K/AKT/mTOR pathway and has been implicated in cancer. High throughput screening versus p70S6K led to the identification of aminopyrimidine 3a as active inhibitor. Lead optimization of 3a resulted in highly potent, selective, and orally bioavailable pyrazolopyrimidines. In this manuscript we report the structure-activity relationship of this series and pharmacokinetic, pharmacodynamic, and efficacy data of the lead compound 13c. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.105
• 作为产物：
  描述：

  异丁酰氯 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 26.0h， 以96%的产率得到2-Cyano-3-hydroxy-4-methyl-2-pentennitril
  参考文献：
  名称：

  [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO
  [FR] INHIBITEURS DE KINASES DEPENDANT DES CYCLINES, COMPOSITIONS ET UTILISATIONS ASSOCIEES

  摘要：

  公开号：

  WO2004092139A3

文献信息

• Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction
  申请人：Pfizer Inc.

  公开号：US06407114B1

  公开（公告）日：2002-06-18

  There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, R4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.

  提供了式IA和式IB的化合物， 其中R1、R2、R3、R4和A的含义如描述中所示，在治疗和预防需要抑制环状鸟苷3′,5′-单磷酸酯酶（例如cGMP PDE5）的医疗状况中非常有用。
• [EN] PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE SOUS FORME DE PYRAZOLOPYRIMIDINES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004009602A1

  公开（公告）日：2004-01-29

  The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.

  本发明一般涉及激酶的抑制剂，更具体地涉及新型吡唑吡嘧啶化合物。
• Comprehensive Study of the Organic-Solvent-Free CDI-Mediated Acylation of Various Nucleophiles by Mechanochemistry
  作者：Thomas-Xavier Métro、Julien Bonnamour、Thomas Reidon、Anthony Duprez、Jordi Sarpoulet、Jean Martinez、Frédéric Lamaty

  DOI：10.1002/chem.201501325

  日期：2015.9.1

  in the synthesis of natural products and biologically active compounds. Unfortunately, these reactions often require the use of large quantities of volatile and/or toxic solvents, either for the reaction, purification or isolation of the products. Herein we describe and discuss the possibility of completely eliminating the use of organic solvents for the synthesis, purification and isolation of products

  酰化反应在天然产物和生物活性化合物的合成中无处不在。不幸的是，这些反应通常需要使用大量的挥发性和/或有毒溶剂，用于反应，纯化或分离产物。本文中，我们描述和讨论了完全消除有机溶剂用于合成，纯化和分离由胺和其他亲核试剂酰化产生的产物的可能性。因此，利用N，N'羰基二咪唑（CDI）可在无溶剂机械搅拌下实现羧酸与各种亲核试剂之间的高效偶联，而水助研磨可实现纯产物的纯化和分离。分析和讨论了关键参数，例如产品的物理状态和水溶性，研磨材料，搅拌类型（振动或行星式搅拌）以及磨损造成的污染。此外，提出了原始的无溶剂有机溶剂条件，以克服这种方法的局限性。其中包括各种绿色指标的计算，突出了此策略对环境的影响特别小。
• SULFONYLUREIDOPYRAZOLE DERIVATIVES
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0885890A1

  公开（公告）日：1998-12-23

  A sulfonylureidopyrazole derivative of formula (1) or (2) is disclosed. The derivative has an inhibitory activity on endothelin converting enzyme, and is useful for treating or preventing various cardiac failures, tracheal constrictions, nervous disorders, parasecretion, vascular disorders, various ulcers and the like.

  公开了一种化学式（1）或（2）的磺酰脲吡唑衍生物。该衍生物对内皮素转化酶具有抑制活性，可用于治疗或预防各种心脏衰竭、气管收缩、神经紊乱、副分泌、血管紊乱、各种溃疡等疾病。
• Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
  申请人：GPC Biotech, Inc.

  公开号：US20040266854A1

  公开（公告）日：2004-12-30

  The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation. Such compounds would be useful for treating subjects having disorders associated with excessive cell proliferation.

  这项发明涉及新型细胞周期依赖性激酶抑制剂（cdks），具体而言，但不仅限于作为cdk/cyclin复合物的抑制剂。如本文所述，本发明的抑制剂能够抑制细胞周期机制，因此可能有助于调节细胞周期进程，最终控制细胞生长和分化。这样的化合物对于治疗患有与过度细胞增殖相关的疾病的患者将会很有用。